Skip to content

Evolus

US · EOLS #3736 by market cap Listed 2018
6.52 -0.48 -6.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 6.79 -3.00%
After-hours 6.50 -0.31%
9.305.556.522026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on EOLS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -11.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 9.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 66.3% Better than 80%
Operating margin -12.7% Better than 14%
Net margin -17.4% Better than 13%
Return on equity -148.3% Better than 4%
Return on invested capital -54.3% Better than 5%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -22.3% Better than 28%
6-month return 7.1% Better than 68%
12-month return (ex latest month) 8.2% Better than 43%
Distance below 52-week high 30.0% Better than 43%
Financial Health D

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.9x Better than 53%
Debt to assets 68.6% Better than 6%
Interest coverage -1.6x Better than 21%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 149.2% Better than 90%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.32%
1M -11.53%
3M -21.92%
6M -1.06%
YTD -1.95%
1Y -1.51%
3Y -33.74%
5Y +2.19%

Key statistics

Price & volume

Prev close
7.00
Open
6.85
Day range
6.50 - 7.19
Avg price
6.78
Volume
813.65K
Turnover
5.51M
Amplitude
9.86%
52-week range
3.86 - 9.31

Valuation

P/E
-8.15
P/E (TTM)
-13.58
P/B
-11.42
EPS
-0.80
Net profit
-52.95M
Net assets
-37.79M

Share structure

Market cap
431.55M
Float cap
310.74M
Shares out
66.19M
Float shares
47.66M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-02-08
52-week range 49% of range
3.86 9.31

30.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-1.58M net over the window

Short interest

Shares short
6.02M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Evolus (EOLS)?

Evolus last traded at 6.52. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Evolus's market cap?

About 431.55M.

What is the P/E ratio of Evolus?

The trailing twelve-month P/E is -13.58. The Valuation tab shows it against the stock's own five-year range.

Does Evolus pay a dividend?

Evolus does not currently pay a regular dividend.

Is Evolus a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 16.25, which implies 149.2% upside from the current price. This is not investment advice.

What is Evolus's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Evolus a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Evolus discussion 0 comments

Add a comment